Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction
Authors:
- Stefan NierkensSNStefan Nierkens
- Jori A. WagenaarsJWJori A. Wagenaars
- Theo J. RuersTRTheo J. Ruers
- Carla C. SchrierCSCarla C. Schrier
- Eric O. RijkeEREric O. Rijke
- Gosse J. AdemaGAGosse J. Adema
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Vaccine adjuvants: A priority for vaccine researchVaccine, 2010
- ISCOMs and ISCOMATRIX™Vaccine, 2009
- Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvantImmunology & Cell Biology, 2009
- Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant MelanomaClinical Cancer Research, 2009
- ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccinesExpert Review of Vaccines, 2007
- Mouse Studies Question Importance of Toll-Like Receptors to VaccinesScience, 2006
- Aluminium compounds for use in vaccinesImmunology & Cell Biology, 2004
- In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor ImmunityCancer Research, 2004
- Dendritic cell immunotherapy: mapping the wayNature Medicine, 2004
- Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped virusesNature, 1984